Skip to main content
SpringerLink
Log in

Quels axes de recherche dans le domaine particulier de la thrombose associée au cancer ?

What direction should research take in the specific area of cancer-associated thrombosis?

  • Mise au point / Update
  • Published:
Oncologie

Abstract

The prevention of venous thromboembolism in patients suffering from cancer is currently a major research topic. Antithrombotic prophylaxis may have a clinical benefit in patients undergoing cancer therapy, but no study clearly identifies a group of patients who may benefit from such a prophylaxis, except after oncological abdominal surgery or for patients treated for myeloma. On the other hand, cancer screening procedures, especially in case of idiopathic VTE, remain a diagnostic challenge. Although extensive screening allows earlier detection of malignancies, the impact on survival has not been demonstrated and cost effectiveness remains to be assessed.

Résumé

La prévention de la maladie veineuse thromboembolique (MVTE) en cas de cancer est un axe de recherchemajeur et d’actualité. La thromboprophylaxie pourrait avoir un intérêt au cours du traitement des cancers, mais aucune étude ne permet d’identifier clairement un groupe de patients dont la survie serait améliorée par ce traitement, en dehors des chirurgies carcinologiques abdominales et des patients traités pour un myélome. Par ailleurs, le dépistage des cancers en cas de MVTE dite idiopathique est aussi un axe de recherche. Bien qu’un bilan exhaustif permette de découvrir des cancers plus précocement, l’impact de ce dépistage sur la survie n’est pas démontré, et le coût reste à évaluer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Agnelli G, George DJ, Kakkar AK, et al. (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366: 601–609

    Article  PubMed  CAS  Google Scholar 

  2. Agnelli G, Gussoni G, Bianchini C, et al. (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10: 943–949

    Article  PubMed  CAS  Google Scholar 

  3. Altinbas M, Coskun HS, Er O, et al. (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2: 1266–1271

    Article  PubMed  CAS  Google Scholar 

  4. Baron JA, Gridley G, Weiderpass E, et al. (1998) Venous thromboembolism and cancer. Lancet 351: 1077–1080

    Article  PubMed  CAS  Google Scholar 

  5. Blom JW, Vanderschoot JP, Oostindier MJ, et al. (2006) Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4: 529–535

    Article  PubMed  CAS  Google Scholar 

  6. Bura A, Cailleux N, Bienvenu B, et al. (2004) Incidence and prognosis of cancer associated with bilateral venous thrombosis: a prospective study of 103 patients. J Thromb Haemost 2: 441–444

    Article  PubMed  CAS  Google Scholar 

  7. Carrier M, Le Gal G, Wells PS, et al. (2008) Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med 149: 323–333

    PubMed  Google Scholar 

  8. Chew HK, Wun T, Harvey D, et al. (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166: 458–464

    PubMed  Google Scholar 

  9. Kakkar AK, Levine MN, Kadziola Z, et al. (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22: 1944–1948

    Article  PubMed  CAS  Google Scholar 

  10. Khorana AA, Francis CW, Menzies KE, et al. (2008) Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 6: 1983–1985

    Article  PubMed  CAS  Google Scholar 

  11. Khorana AA, Kuderer NM, Culakova E, et al. (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111: 4902–4907

    Article  PubMed  CAS  Google Scholar 

  12. Klerk CP, Smorenburg SM, Otten HM, et al. (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23: 2130–2135

    Article  PubMed  CAS  Google Scholar 

  13. Kuderer NM, Ortel TL, Francis CW (2009) Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 27: 4902–4911

    Article  PubMed  CAS  Google Scholar 

  14. Mousa SA, Petersen LJ (2009) Anticancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost 102: 258–267

    PubMed  CAS  Google Scholar 

  15. Piccioli A, Lensing AW, Prins MH, et al. (2004) Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2: 884–889

    Article  PubMed  CAS  Google Scholar 

  16. Rieu V, Chanier S, Philippe P, et al. (2011) Systematic screening for occult cancer in elderly patients with venous thromboembolism: a prospective study. Intern Med J 41: 769–775

    Article  PubMed  CAS  Google Scholar 

  17. Sideras K, Schaefer PL, Okuno SH, et al. (2006) Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 81: 758–767

    Article  PubMed  CAS  Google Scholar 

  18. Van Doormaal FF, Terpstra W, Van Der Griend R, et al. (2011) Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost 9: 79–84

    Article  PubMed  Google Scholar 

  19. White RH, Chew HK, Zhou H, et al. (2005) Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 165: 1782–1787

    Article  PubMed  Google Scholar 

  20. Zwicker JI (2010) Predictive value of tissue factor bearing microparticles in cancer associated thrombosis. Thromb Res 125(Suppl 2): S89–S91

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de médecine nucléaire, université européenne de Bretagne, université de Brest, EA3878 (GETBO) IFR 148, CHRU Cavale Blanche, Brest, France

    P. -Y. Le Roux, P. Robin & P. -Y. Salaun

  2. Département de médecine interne et de pneumologie, université européenne de Bretagne, université de Brest, EA3878 (GETBO) IFR148, CHRU Cavale Blanche, Brest, France

    A. Delluc

  3. Département de médecine interne et de pneumologie, université européenne de Bretagne, université de Brest, Inserm CIC 05-02 IFR148, CHRU Cavale Blanche, Brest, France

    G. Le Gal

Authors
  1. P. -Y. Le Roux
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Delluc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Le Gal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. -Y. Salaun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. -Y. Le Roux.

About this article

Cite this article

Le Roux, P.Y., Delluc, A., Robin, P. et al. Quels axes de recherche dans le domaine particulier de la thrombose associée au cancer ?. Oncologie 14, 663–666 (2012). https://doi.org/10.1007/s10269-012-2233-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-012-2233-y

Keywords

Mots clés

Search

Navigation